Dernière synchronisation : 29 novembre 2023 Avis - Les informations proviennent de registres publics et peuvent ne pas refléter les changements en temps réel sur le site local.
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19 positive relapsed or refractory acute myeloid leukemia.